Tin tức & Cập nhật

Chỉ hiển thị Multimedia
BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis

BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis

12 Dec 2023 bởiJairia Dela Cruz

In the treatment of patients with rifampicin-resistant tuberculosis, a 6-month oral regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is safe and efficacious and compares favourably with standard of care, as shown in the final data from the phase IIB-III TB-PRACTECAL study.

BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis

12 Dec 2023
Benralizumab appears superior to mepolizumab in severe eosinophilic asthma

Benralizumab appears superior to mepolizumab in severe eosinophilic asthma

12 Dec 2023 bởiStephen Padilla

Both mepolizumab and benralizumab are effective in improving the clinical outcomes of patients with severe eosinophilic asthma, as shown in a recent study. However, treatment with benralizumab appears to be better than mepolizumab in reducing exacerbations, improving forced expiratory volume, and depleting blood eosinophils.

Benralizumab appears superior to mepolizumab in severe eosinophilic asthma

12 Dec 2023
One in six CYPs in SG develop long COVID

One in six CYPs in SG develop long COVID

11 Dec 2023